Kathleen Victoria Fitch, M.S.N.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 85 | 2024 | 16678 | 3.320 |
Why?
|
Plaque, Atherosclerotic | 16 | 2024 | 1499 | 1.540 |
Why?
|
Coronary Artery Disease | 21 | 2024 | 6454 | 1.180 |
Why?
|
Cardiovascular Diseases | 22 | 2024 | 15108 | 1.050 |
Why?
|
HIV | 12 | 2023 | 1600 | 1.050 |
Why?
|
Sweetening Agents | 2 | 2022 | 296 | 0.870 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 10 | 2023 | 3239 | 0.860 |
Why?
|
Atherosclerosis | 9 | 2024 | 3428 | 0.720 |
Why?
|
Life Style | 5 | 2019 | 3824 | 0.720 |
Why?
|
Amino Acids | 3 | 2020 | 1727 | 0.650 |
Why?
|
Diet Therapy | 1 | 2019 | 154 | 0.650 |
Why?
|
Quinolines | 7 | 2023 | 719 | 0.630 |
Why?
|
HIV-Associated Lipodystrophy Syndrome | 5 | 2021 | 138 | 0.580 |
Why?
|
Multicenter Studies as Topic | 3 | 2020 | 1661 | 0.560 |
Why?
|
Renin-Angiotensin System | 6 | 2022 | 759 | 0.500 |
Why?
|
Monocytes | 4 | 2018 | 2593 | 0.500 |
Why?
|
Fibrosis | 2 | 2018 | 2026 | 0.440 |
Why?
|
Bone Diseases | 2 | 2019 | 416 | 0.440 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 5 | 2018 | 293 | 0.420 |
Why?
|
Adiposity | 7 | 2021 | 1806 | 0.420 |
Why?
|
Inflammation | 15 | 2023 | 10578 | 0.420 |
Why?
|
Tunica Media | 2 | 2011 | 113 | 0.400 |
Why?
|
Middle Aged | 74 | 2024 | 213127 | 0.400 |
Why?
|
Dyslipidemias | 3 | 2019 | 848 | 0.380 |
Why?
|
Asymptomatic Diseases | 5 | 2018 | 552 | 0.380 |
Why?
|
Nutrition Disorders | 1 | 2011 | 211 | 0.380 |
Why?
|
Patient Selection | 2 | 2020 | 4214 | 0.370 |
Why?
|
Subcutaneous Fat | 5 | 2019 | 391 | 0.370 |
Why?
|
Tunica Intima | 2 | 2011 | 464 | 0.350 |
Why?
|
Intra-Abdominal Fat | 4 | 2019 | 591 | 0.340 |
Why?
|
Metformin | 2 | 2014 | 829 | 0.330 |
Why?
|
Aging | 3 | 2020 | 8626 | 0.320 |
Why?
|
Fingers | 1 | 2011 | 514 | 0.310 |
Why?
|
Arteritis | 2 | 2022 | 159 | 0.310 |
Why?
|
Neck | 2 | 2016 | 693 | 0.310 |
Why?
|
Adipose Tissue | 6 | 2023 | 3278 | 0.300 |
Why?
|
Diet | 4 | 2022 | 7923 | 0.300 |
Why?
|
Adipose Tissue, Brown | 4 | 2019 | 754 | 0.290 |
Why?
|
Anti-HIV Agents | 9 | 2020 | 4250 | 0.290 |
Why?
|
Ribonuclease III | 2 | 2021 | 275 | 0.290 |
Why?
|
Male | 72 | 2024 | 349538 | 0.290 |
Why?
|
Cytomegalovirus Infections | 2 | 2024 | 817 | 0.290 |
Why?
|
Anti-Retroviral Agents | 6 | 2023 | 1712 | 0.290 |
Why?
|
Carotid Arteries | 1 | 2011 | 952 | 0.280 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2022 | 9941 | 0.280 |
Why?
|
Viral Nonstructural Proteins | 1 | 2018 | 241 | 0.270 |
Why?
|
DEAD-box RNA Helicases | 2 | 2021 | 375 | 0.270 |
Why?
|
Female | 71 | 2024 | 379592 | 0.270 |
Why?
|
Humans | 96 | 2024 | 742088 | 0.260 |
Why?
|
Body Composition | 12 | 2019 | 2400 | 0.260 |
Why?
|
Calcinosis | 2 | 2012 | 1497 | 0.260 |
Why?
|
Drug Resistance, Viral | 2 | 2023 | 820 | 0.260 |
Why?
|
Adult | 47 | 2023 | 213712 | 0.250 |
Why?
|
Risk Factors | 23 | 2024 | 72145 | 0.250 |
Why?
|
Risk Reduction Behavior | 1 | 2011 | 1123 | 0.240 |
Why?
|
Receptors, Cell Surface | 5 | 2018 | 2867 | 0.240 |
Why?
|
HIV Integrase Inhibitors | 2 | 2023 | 142 | 0.240 |
Why?
|
Viral Load | 8 | 2022 | 3292 | 0.230 |
Why?
|
Exercise | 1 | 2019 | 5611 | 0.220 |
Why?
|
Insulin Resistance | 6 | 2021 | 3861 | 0.220 |
Why?
|
Nutritional Status | 1 | 2011 | 1606 | 0.220 |
Why?
|
Antigens, CD | 5 | 2018 | 4024 | 0.220 |
Why?
|
Sex Factors | 7 | 2019 | 10392 | 0.220 |
Why?
|
Body Mass Index | 10 | 2023 | 12695 | 0.210 |
Why?
|
HIV Integrase | 1 | 2023 | 120 | 0.210 |
Why?
|
Blood Proteins | 3 | 2023 | 1122 | 0.200 |
Why?
|
Subcutaneous Fat, Abdominal | 2 | 2019 | 92 | 0.190 |
Why?
|
Hepacivirus | 1 | 2018 | 1372 | 0.180 |
Why?
|
Lipoproteins, LDL | 3 | 2022 | 628 | 0.180 |
Why?
|
Proteomics | 4 | 2023 | 3618 | 0.180 |
Why?
|
HIV-1 | 6 | 2023 | 6934 | 0.180 |
Why?
|
HIV Long-Term Survivors | 1 | 2020 | 126 | 0.180 |
Why?
|
Hypoglycemic Agents | 1 | 2012 | 2866 | 0.170 |
Why?
|
Hyperinsulinism | 2 | 2017 | 415 | 0.170 |
Why?
|
Prevalence | 7 | 2022 | 15194 | 0.170 |
Why?
|
AIDS-Associated Nephropathy | 1 | 2019 | 35 | 0.170 |
Why?
|
Absorptiometry, Photon | 2 | 2019 | 1726 | 0.160 |
Why?
|
Serum | 2 | 2019 | 212 | 0.160 |
Why?
|
Endothelium, Vascular | 1 | 2011 | 4455 | 0.160 |
Why?
|
Cross-Sectional Studies | 9 | 2023 | 24913 | 0.160 |
Why?
|
Young Adult | 15 | 2021 | 56350 | 0.160 |
Why?
|
Comorbidity | 5 | 2020 | 10372 | 0.160 |
Why?
|
Methylamines | 2 | 2016 | 117 | 0.160 |
Why?
|
Research Subjects | 1 | 2020 | 238 | 0.160 |
Why?
|
Coronary Angiography | 6 | 2024 | 4567 | 0.160 |
Why?
|
Heart Diseases | 1 | 2011 | 2789 | 0.160 |
Why?
|
Anti-Mullerian Hormone | 1 | 2020 | 399 | 0.160 |
Why?
|
Hepatitis C | 1 | 2018 | 1582 | 0.150 |
Why?
|
Cholesterol, LDL | 5 | 2024 | 2354 | 0.150 |
Why?
|
Natriuretic Peptides | 1 | 2018 | 150 | 0.140 |
Why?
|
Tomography, X-Ray | 1 | 2016 | 60 | 0.140 |
Why?
|
Food Supply | 1 | 2022 | 517 | 0.140 |
Why?
|
Adolescent | 18 | 2021 | 85649 | 0.140 |
Why?
|
Angiography | 3 | 2016 | 1636 | 0.140 |
Why?
|
CD4 Lymphocyte Count | 5 | 2020 | 2557 | 0.140 |
Why?
|
Smoking | 1 | 2013 | 8969 | 0.130 |
Why?
|
Reverse Transcriptase Inhibitors | 3 | 2022 | 615 | 0.130 |
Why?
|
Muscle Cells | 1 | 2016 | 196 | 0.130 |
Why?
|
Sodium | 2 | 2022 | 1627 | 0.130 |
Why?
|
Glomerular Filtration Rate | 2 | 2020 | 2167 | 0.130 |
Why?
|
Triglycerides | 3 | 2020 | 2450 | 0.130 |
Why?
|
Antiviral Agents | 1 | 2018 | 2978 | 0.130 |
Why?
|
Macrophage Activation | 1 | 2018 | 558 | 0.130 |
Why?
|
Aged | 20 | 2023 | 162944 | 0.130 |
Why?
|
Pravastatin | 1 | 2017 | 395 | 0.130 |
Why?
|
Gender Identity | 1 | 2020 | 681 | 0.120 |
Why?
|
Nutrition Policy | 1 | 2019 | 488 | 0.120 |
Why?
|
Diet Surveys | 1 | 2019 | 1172 | 0.120 |
Why?
|
Coronary Vessels | 4 | 2023 | 3099 | 0.120 |
Why?
|
Interleukin-10 | 1 | 2020 | 1200 | 0.120 |
Why?
|
Behavior Therapy | 1 | 2019 | 866 | 0.120 |
Why?
|
Blood Coagulation Disorders | 1 | 2016 | 337 | 0.110 |
Why?
|
International Cooperation | 1 | 2020 | 1421 | 0.110 |
Why?
|
Cholesterol, HDL | 2 | 2013 | 1813 | 0.110 |
Why?
|
Pericardium | 1 | 2018 | 667 | 0.110 |
Why?
|
Regression Analysis | 3 | 2013 | 6452 | 0.110 |
Why?
|
Adipose Tissue, White | 1 | 2016 | 345 | 0.110 |
Why?
|
Double-Blind Method | 7 | 2023 | 12017 | 0.110 |
Why?
|
Chemokine CXCL10 | 1 | 2013 | 304 | 0.110 |
Why?
|
Boston | 2 | 2019 | 9305 | 0.110 |
Why?
|
Minority Groups | 1 | 2020 | 1215 | 0.110 |
Why?
|
Menopause | 1 | 2020 | 1621 | 0.110 |
Why?
|
1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2023 | 127 | 0.100 |
Why?
|
Anticholesteremic Agents | 2 | 2017 | 979 | 0.100 |
Why?
|
Sex Characteristics | 2 | 2023 | 2585 | 0.100 |
Why?
|
Tomography, X-Ray Computed | 7 | 2019 | 20086 | 0.100 |
Why?
|
Fenofibrate | 1 | 2011 | 88 | 0.100 |
Why?
|
Cardiovascular System | 1 | 2018 | 827 | 0.100 |
Why?
|
Fibronectins | 1 | 2014 | 723 | 0.090 |
Why?
|
Case-Control Studies | 7 | 2020 | 21719 | 0.090 |
Why?
|
Niacin | 1 | 2011 | 116 | 0.090 |
Why?
|
Proteome | 1 | 2020 | 1790 | 0.090 |
Why?
|
Prospective Studies | 8 | 2022 | 53187 | 0.090 |
Why?
|
Iodide Peroxidase | 1 | 2012 | 293 | 0.090 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2018 | 2014 | 0.090 |
Why?
|
Osteoporosis | 1 | 2019 | 1581 | 0.090 |
Why?
|
Pulsatile Flow | 1 | 2011 | 332 | 0.090 |
Why?
|
Intestinal Diseases | 1 | 2015 | 531 | 0.090 |
Why?
|
Hyperemia | 1 | 2011 | 224 | 0.090 |
Why?
|
Vaccination | 1 | 2022 | 3256 | 0.090 |
Why?
|
North America | 2 | 2024 | 1249 | 0.090 |
Why?
|
Drug Therapy, Combination | 2 | 2018 | 6483 | 0.090 |
Why?
|
Vitamin D Deficiency | 1 | 2019 | 1331 | 0.080 |
Why?
|
Cytomegalovirus | 2 | 2024 | 730 | 0.080 |
Why?
|
Primary Prevention | 3 | 2023 | 1166 | 0.080 |
Why?
|
Manometry | 1 | 2011 | 444 | 0.080 |
Why?
|
Calorimetry, Indirect | 1 | 2009 | 183 | 0.080 |
Why?
|
Mass Spectrometry | 1 | 2016 | 2203 | 0.080 |
Why?
|
Fibroblast Growth Factors | 1 | 2014 | 879 | 0.080 |
Why?
|
Blood Pressure | 4 | 2018 | 8541 | 0.080 |
Why?
|
Lipodystrophy | 2 | 2006 | 147 | 0.080 |
Why?
|
Cardiomyopathies | 1 | 2020 | 1912 | 0.080 |
Why?
|
Blood Glucose | 3 | 2021 | 6249 | 0.080 |
Why?
|
Antibodies, Viral | 3 | 2024 | 3164 | 0.080 |
Why?
|
Immunologic Factors | 1 | 2017 | 1575 | 0.080 |
Why?
|
Patient Participation | 1 | 2017 | 1445 | 0.080 |
Why?
|
Stavudine | 1 | 2007 | 85 | 0.070 |
Why?
|
Extremities | 1 | 2012 | 865 | 0.070 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2012 | 2013 | 0.070 |
Why?
|
Adipogenesis | 2 | 2021 | 358 | 0.070 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2020 | 2195 | 0.070 |
Why?
|
Hyperlipidemias | 1 | 2011 | 786 | 0.070 |
Why?
|
Hypertension | 2 | 2019 | 8455 | 0.070 |
Why?
|
Treatment Outcome | 8 | 2018 | 62966 | 0.070 |
Why?
|
Mitochondria, Muscle | 1 | 2007 | 171 | 0.070 |
Why?
|
Liver | 2 | 2021 | 7470 | 0.070 |
Why?
|
Immunity | 1 | 2011 | 1011 | 0.070 |
Why?
|
Energy Metabolism | 3 | 2016 | 2896 | 0.070 |
Why?
|
MicroRNAs | 1 | 2021 | 3731 | 0.070 |
Why?
|
Cholesterol | 1 | 2014 | 2895 | 0.070 |
Why?
|
Vitamin D | 1 | 2019 | 3211 | 0.060 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2019 | 839 | 0.060 |
Why?
|
Evidence-Based Medicine | 1 | 2017 | 3611 | 0.060 |
Why?
|
Health Promotion | 1 | 2017 | 2194 | 0.060 |
Why?
|
Chi-Square Distribution | 1 | 2011 | 3510 | 0.060 |
Why?
|
RNA, Messenger | 1 | 2019 | 13029 | 0.060 |
Why?
|
Back | 2 | 2016 | 66 | 0.060 |
Why?
|
Age Factors | 3 | 2020 | 18355 | 0.060 |
Why?
|
Chemokine CCL2 | 2 | 2017 | 617 | 0.060 |
Why?
|
Exercise Therapy | 1 | 2011 | 904 | 0.060 |
Why?
|
Aldosterone | 2 | 2022 | 876 | 0.060 |
Why?
|
Heart | 1 | 2017 | 4462 | 0.060 |
Why?
|
Diet, Sodium-Restricted | 2 | 2016 | 287 | 0.060 |
Why?
|
Wounds and Injuries | 1 | 2016 | 2400 | 0.060 |
Why?
|
Body Size | 1 | 2006 | 461 | 0.060 |
Why?
|
Glucose Clamp Technique | 2 | 2018 | 266 | 0.060 |
Why?
|
Waist Circumference | 2 | 2019 | 917 | 0.060 |
Why?
|
United States | 5 | 2023 | 69693 | 0.050 |
Why?
|
Protease Inhibitors | 1 | 2006 | 790 | 0.050 |
Why?
|
Up-Regulation | 1 | 2012 | 4211 | 0.050 |
Why?
|
Lipids | 2 | 2018 | 3302 | 0.050 |
Why?
|
Nucleosides | 1 | 2022 | 138 | 0.050 |
Why?
|
Eating | 1 | 2009 | 1535 | 0.050 |
Why?
|
CCN Intercellular Signaling Proteins | 1 | 2021 | 25 | 0.050 |
Why?
|
Latent TGF-beta Binding Proteins | 1 | 2021 | 42 | 0.050 |
Why?
|
Treatment Failure | 1 | 2018 | 2615 | 0.050 |
Why?
|
Lymphocyte Activation | 1 | 2012 | 5519 | 0.050 |
Why?
|
Immunoglobulin G | 2 | 2024 | 4554 | 0.050 |
Why?
|
Risk Assessment | 4 | 2022 | 23320 | 0.050 |
Why?
|
Polycystic Ovary Syndrome | 1 | 2005 | 369 | 0.050 |
Why?
|
Diabetes Mellitus | 1 | 2019 | 5724 | 0.050 |
Why?
|
Obesity | 2 | 2022 | 12705 | 0.050 |
Why?
|
CD4-CD8 Ratio | 1 | 2020 | 112 | 0.050 |
Why?
|
Statistical Distributions | 1 | 2020 | 64 | 0.050 |
Why?
|
Obesity, Abdominal | 2 | 2015 | 361 | 0.050 |
Why?
|
Receptors, Purinergic P2X5 | 1 | 2019 | 6 | 0.050 |
Why?
|
Ultrasonography | 2 | 2011 | 5978 | 0.050 |
Why?
|
Integrases | 1 | 2022 | 533 | 0.040 |
Why?
|
Muscle, Skeletal | 2 | 2023 | 4933 | 0.040 |
Why?
|
Oxygen Consumption | 1 | 2006 | 1869 | 0.040 |
Why?
|
Amino Acid Transport Systems, Neutral | 1 | 2019 | 41 | 0.040 |
Why?
|
Massachusetts | 1 | 2013 | 8662 | 0.040 |
Why?
|
Reproduction | 2 | 2020 | 668 | 0.040 |
Why?
|
Positron-Emission Tomography | 2 | 2012 | 6259 | 0.040 |
Why?
|
Interleukin-18 | 1 | 2021 | 248 | 0.040 |
Why?
|
Dietary Fats | 1 | 2007 | 2017 | 0.040 |
Why?
|
Glucose | 2 | 2012 | 4391 | 0.040 |
Why?
|
Muscles | 1 | 2024 | 1617 | 0.040 |
Why?
|
Phenotype | 1 | 2016 | 16331 | 0.040 |
Why?
|
DNA Mutational Analysis | 1 | 2018 | 4187 | 0.040 |
Why?
|
Alanine Transaminase | 1 | 2021 | 592 | 0.040 |
Why?
|
Multivariate Analysis | 2 | 2009 | 12242 | 0.040 |
Why?
|
Cohort Studies | 5 | 2021 | 40450 | 0.040 |
Why?
|
HIV Protease Inhibitors | 1 | 2019 | 430 | 0.040 |
Why?
|
Receptors, Interleukin-1 | 1 | 2018 | 261 | 0.040 |
Why?
|
Congresses as Topic | 1 | 2022 | 764 | 0.040 |
Why?
|
Growth Differentiation Factor 15 | 1 | 2018 | 176 | 0.040 |
Why?
|
Blood Chemical Analysis | 1 | 2019 | 440 | 0.040 |
Why?
|
Transsexualism | 1 | 2020 | 177 | 0.040 |
Why?
|
Symporters | 1 | 2019 | 363 | 0.040 |
Why?
|
Hormones | 2 | 2014 | 884 | 0.040 |
Why?
|
Antiretroviral Therapy, Highly Active | 2 | 2020 | 1872 | 0.040 |
Why?
|
Galectin 3 | 1 | 2018 | 227 | 0.030 |
Why?
|
Cytoskeletal Proteins | 1 | 2021 | 1363 | 0.030 |
Why?
|
History, 21st Century | 1 | 2022 | 1533 | 0.030 |
Why?
|
Radiography, Abdominal | 1 | 2019 | 537 | 0.030 |
Why?
|
Galectins | 1 | 2018 | 267 | 0.030 |
Why?
|
Malnutrition | 1 | 2022 | 625 | 0.030 |
Why?
|
Gene Silencing | 1 | 2021 | 1538 | 0.030 |
Why?
|
Gene Expression | 2 | 2019 | 7790 | 0.030 |
Why?
|
Magnetic Resonance Spectroscopy | 2 | 2020 | 3760 | 0.030 |
Why?
|
Adipocytes | 1 | 2021 | 1182 | 0.030 |
Why?
|
Body Fat Distribution | 1 | 2016 | 244 | 0.030 |
Why?
|
Glucose Tolerance Test | 1 | 2017 | 1150 | 0.030 |
Why?
|
Down-Regulation | 1 | 2021 | 3001 | 0.030 |
Why?
|
Choline | 1 | 2015 | 487 | 0.030 |
Why?
|
Genotype | 1 | 2018 | 12946 | 0.030 |
Why?
|
Income | 1 | 2021 | 1904 | 0.030 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2016 | 1574 | 0.030 |
Why?
|
Angiotensin II | 1 | 2015 | 881 | 0.030 |
Why?
|
Community Health Services | 1 | 2017 | 650 | 0.030 |
Why?
|
Self Report | 1 | 2022 | 3548 | 0.020 |
Why?
|
Placebos | 1 | 2016 | 1677 | 0.020 |
Why?
|
Spleen | 1 | 2017 | 2359 | 0.020 |
Why?
|
RNA, Viral | 1 | 2020 | 2899 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2016 | 1866 | 0.020 |
Why?
|
Mesenchymal Stem Cells | 1 | 2021 | 1625 | 0.020 |
Why?
|
Drug Interactions | 1 | 2015 | 1458 | 0.020 |
Why?
|
Abdominal Fat | 1 | 2012 | 223 | 0.020 |
Why?
|
Disease Susceptibility | 1 | 2018 | 1780 | 0.020 |
Why?
|
Residence Characteristics | 1 | 2020 | 2049 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2021 | 3020 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2023 | 4379 | 0.020 |
Why?
|
Hypertrophy | 1 | 2012 | 568 | 0.020 |
Why?
|
American Heart Association | 1 | 2014 | 1055 | 0.020 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2013 | 11695 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2022 | 3527 | 0.020 |
Why?
|
Communication | 1 | 2022 | 3728 | 0.020 |
Why?
|
Immunity, Cellular | 1 | 2014 | 1606 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2018 | 3199 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2021 | 5019 | 0.020 |
Why?
|
Tissue Distribution | 1 | 2012 | 2335 | 0.020 |
Why?
|
Atrophy | 1 | 2012 | 1576 | 0.020 |
Why?
|
Body Constitution | 1 | 2007 | 278 | 0.020 |
Why?
|
Health Status | 1 | 2020 | 4030 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2017 | 2275 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2021 | 14554 | 0.020 |
Why?
|
Phosphocreatine | 1 | 2007 | 269 | 0.020 |
Why?
|
Phosphorus | 1 | 2007 | 338 | 0.020 |
Why?
|
Carotid Artery, Common | 1 | 2006 | 183 | 0.020 |
Why?
|
Research Design | 1 | 2020 | 5979 | 0.020 |
Why?
|
Hypertriglyceridemia | 1 | 2007 | 293 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2021 | 11470 | 0.010 |
Why?
|
Menstruation | 1 | 2005 | 299 | 0.010 |
Why?
|
Homeostasis | 1 | 2014 | 3335 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8328 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2019 | 7873 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2019 | 9639 | 0.010 |
Why?
|
Epidemiologic Methods | 1 | 2007 | 1364 | 0.010 |
Why?
|
Thorax | 1 | 2005 | 547 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 2023 | 11690 | 0.010 |
Why?
|
DNA, Mitochondrial | 1 | 2007 | 814 | 0.010 |
Why?
|
Protons | 1 | 2007 | 1126 | 0.010 |
Why?
|
Contrast Media | 1 | 2014 | 5295 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2017 | 7901 | 0.010 |
Why?
|
Ovary | 1 | 2005 | 981 | 0.010 |
Why?
|
Anthropometry | 1 | 2005 | 1350 | 0.010 |
Why?
|
Transcription Factors | 1 | 2019 | 12164 | 0.010 |
Why?
|
Biopsy | 1 | 2012 | 6756 | 0.010 |
Why?
|
Energy Intake | 1 | 2007 | 2147 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2014 | 9410 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2014 | 7276 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2014 | 12071 | 0.010 |
Why?
|
Disease Progression | 1 | 2012 | 13256 | 0.010 |
Why?
|
Radiography | 1 | 2006 | 7010 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2020 | 57683 | 0.010 |
Why?
|
Mice | 1 | 2021 | 81045 | 0.010 |
Why?
|
Prognosis | 1 | 2015 | 29010 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2007 | 7770 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2020 | 35342 | 0.010 |
Why?
|
Bone Density | 1 | 2005 | 3469 | 0.010 |
Why?
|
Animals | 1 | 2021 | 168561 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2005 | 13921 | 0.010 |
Why?
|
Neoplasms | 1 | 2017 | 21596 | 0.010 |
Why?
|